HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Igor P Dmitriev Selected Research

AD 5

1/2014Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).
5/2012Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.
3/2011A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.
12/2010Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.
6/2010Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Igor P Dmitriev Research Topics

Disease

17Neoplasms (Cancer)
02/2021 - 01/2002
12Infections
10/2020 - 01/2002
7Melanoma (Melanoma, Malignant)
05/2012 - 11/2007
3Ovarian Neoplasms (Ovarian Cancer)
02/2019 - 01/2014
2Communicable Diseases (Infectious Diseases)
01/2018 - 01/2012
2Malaria
01/2017 - 01/2016
2Prostatic Neoplasms (Prostate Cancer)
01/2014 - 05/2011
2Renal Cell Carcinoma (Grawitz Tumor)
03/2011 - 12/2010
2Kidney Neoplasms (Kidney Cancer)
03/2011 - 12/2010
1COVID-19
10/2020
1Inflammation (Inflammations)
10/2020
1Clostridium Infections
09/2016
1Community-Acquired Infections
09/2016
1Edema (Dropsy)
01/2016
1Anthrax
01/2016
1Hemolytic-Uremic Syndrome
01/2015
1Colorectal Neoplasms (Colorectal Cancer)
05/2012
1Disease Progression
01/2011
1Myeloid Leukemia (Leukemia, Myelocytic)
12/2010
1Leukemia
12/2010
1Carcinoma (Carcinomatosis)
06/2010
1Glioblastoma (Glioblastoma Multiforme)
06/2010
1Glioma (Gliomas)
06/2010
1Cicatrix (Scar)
01/2002

Drug/Important Bio-Agent (IBA)

7CytokinesIBA
02/2021 - 11/2007
7InterleukinsIBA
05/2012 - 11/2007
6VaccinesIBA
10/2020 - 01/2012
5AD 5IBA
01/2014 - 06/2010
4Interleukin-10 (Interleukin 10)IBA
05/2011 - 06/2010
4Proteins (Proteins, Gene)FDA Link
12/2010 - 01/2002
3adenovirus receptorIBA
01/2011 - 01/2002
2EpitopesIBA
02/2021 - 01/2016
2Neutralizing AntibodiesIBA
10/2020 - 09/2016
2AntibodiesIBA
10/2020 - 01/2016
2LigandsIBA
01/2017 - 01/2002
2AntigensIBA
01/2017 - 01/2016
2Peptides (Polypeptides)IBA
01/2016 - 01/2002
21,1',6,6',7,7'- hexahydroxy- 3,3'- dimethyl- N5- (2- phenylpropyl)- N5'- (2- phenylpropyl)- 2,2'- binaphthyl- 5,5'- dicarboxamideIBA
05/2012 - 05/2011
2apogossypolIBA
05/2012 - 05/2011
1OsteocalcinIBA
02/2021
1Viral RNAIBA
10/2020
1NucleoproteinsIBA
10/2020
1Immunoglobulin A (IgA)IBA
10/2020
1Biomarkers (Surrogate Marker)IBA
01/2017
1Pharmaceutical PreparationsIBA
01/2017
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2017
1Merozoite Surface Protein 1 (MSA1)IBA
01/2017
1Anti-Bacterial Agents (Antibiotics)IBA
09/2016
1anthrax toxin (anthrax lethal factor)IBA
01/2016
1Shiga Toxin (Shigella Toxin)IBA
01/2015
1Somatostatin Receptors (Somatostatin Receptor)IBA
01/2014
164Cu-CB-TE2A-Y3-TATEIBA
01/2014
1ABT-737IBA
05/2011
1Aligeron (AS 2)IBA
03/2011
1CeramidesIBA
03/2011
1FenretinideIBA
03/2011
1Caspase 8 (Caspase-8)IBA
03/2011
1tanespimycin (17AAG)IBA
03/2011
1Sorafenib (BAY 43-9006)FDA Link
12/2010
1Endoplasmic Reticulum Chaperone BiPIBA
12/2010
1Glucose (Dextrose)FDA LinkGeneric
12/2010
1Peptide Initiation Factors (Initiation Factor)IBA
12/2010
1EnzymesIBA
12/2010
1Small Interfering RNA (siRNA)IBA
12/2010
1Inositol (Myoinositol)IBA
12/2010
1His-His-His-His-His-His ((His)6)IBA
05/2009
1Monoclonal AntibodiesIBA
11/2007
1Viral DNAIBA
02/2006
1PolylysineIBA
07/2002
1Oncogene Proteins (Oncogene Protein)IBA
01/2002

Therapy/Procedure

9Therapeutics
01/2020 - 01/2002
2Drug Therapy (Chemotherapy)
10/2010 - 11/2007
1Intranasal Administration
10/2020
1Immunotherapy
02/2019